MaxCyte CFO’s “Sale to Cover” Quietly Mirrors Strong Executive Buying Momentum, Signals No Confidence Shakeup
MaxCyte insider activity: CFO’s modest $0.82 “sale‑to‑cover” vs. June’s executive buying surge—what it means for a volatile biotech stock poised for growth.
2 minutes to read